PRMT5 (protein arginine methyltransferase 5), MTA-cooperative binding

Class

Small-molecule MTA-cooperative PRMT5 inhibitor

Pathway

Selectively inhibits PRMT5 in tumors with homozygous MTAP deletion, exploiting synthetic lethality via MTA accumulation

PRMT5 (protein arginine methyltransferase 5) is an enzyme that chemically modifies arginine residues on histones and other proteins, influencing gene splicing, transcription, and DNA repair. Because these functions support cell division broadly, blocking PRMT5 outright tends to harm healthy dividing tissue along with tumor cells, limiting the usefulness of non-selective inhibitors. A subset of cancers carry a deletion of the neighboring gene MTAP, which normally clears a metabolic byproduct called MTA (methylthioadenosine). Without MTAP, MTA accumulates inside these tumor cells and partially occupies PRMT5 itself, leaving the enzyme already operating under stress. This creates a therapeutic opportunity: a drug engineered to bind PRMT5 cooperatively alongside the accumulated MTA can achieve much stronger inhibition selectively in MTAP-deleted cells, while largely sparing normal cells that lack this MTA buildup. This approach is an example of synthetic lethality, where a drug's effect depends on a specific genetic lesion already present in the tumor. MTAP deletion occurs across a range of solid and hematologic cancers, making this mechanism broadly relevant wherever that genetic alteration is present, and it represents a strategy for improving the selectivity of PRMT5-targeted therapy relative to earlier, non-selective approaches.